.png)
PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). Besremi (ropeginterferon alfa-2b-njft) is FDA approved for the treatment of adults with polycythemia vera, and is a recommended option by the NCCN Clinical Practice Guidelines in Oncology for both low and high risk PV in multiple treatment settings.
